Últimas noticias sobre Innate Pharma (NASDAQ:IPHA) Bolsa

INNATE PHARMA SA-SPONS ADR

Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

C&amp;F Financial Corporation (the Corporation) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFFI#NASDAQ">CFFI</a>), the holding company for C&amp;F Bank, is proud to announce a significant expansion of its commercial banking operations with a seasoned team that will establish its presence in Southwest Virginia. This strategic move positions C&amp;F to serve key markets including Roanoke, Lynchburg, Danville, Martinsville, and Blacksburg.
Leading this expansion is&nbsp;Matt Hubbard, who joins as&nbsp;Southwest Virginia Regional President. With over 15 years of commercial banking leadership experience, most recently at Atlantic Union Bank, (formerly American National Bank). Matt brings deep market knowledge and a strong commitment to community engagement. He is a graduate of Radford University and the William &amp; Mary Mason School of Business.

CFFI

C&F Financial Expands Commercial Banking Operations, Establishing Its Presence In Southwest Virginia

B of A Securities analyst Michael Funk maintains Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) with a Neutral and raises the price target from $45 to $49.

Price Target

Analyst Ratings

B of A Securities Maintains Neutral on Verizon Communications, Raises Price Target to $49

B of A Securities analyst Geoff Meacham maintains CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Buy and lowers the price target from $79 to $78.

CRSP

B of A Securities Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $78

B of A Securities analyst Alec Stranahan maintains Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Neutral and lowers the price target from $10 to $9.

NVAX

B of A Securities Maintains Neutral on Novavax, Lowers Price Target to $9

B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Buy and lowers the price target from $52 to $51.

AGIO

B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $51

Scotiabank analyst Alfonso Salazar maintains Vale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>) with a Sector Perform and lowers the price target from $13 to $12.5.

VALE

Scotiabank Maintains Sector Perform on Vale, Lowers Price Target to $12.5

Westinghouse Air Brake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) has outperformed the market over the past 5 years by 13.42% on an annualized basis producing an average annual return of 27.62%. Currently, Westinghouse Air Brake has a market capitalization of $35.92 billion. 
Buying $1000 In WAB: If an investor had bought $1000 of WAB stock 5 years ago, it would be worth $3,392.60 today based on a price of $209.88 for WAB at the time of writing.
<h3>Westinghouse Air Brake's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753200914_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Westinghouse Air Brake Stock In The Last 5 Years

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) with a Buy and raises the price target from $27 to $28.

B of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

Live On CNBC, Stephanie Link Announces Bought More Wells Fargo

B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and lowers the price target from $193 to $192.

KRYS

B of A Securities Maintains Buy on Krystal Biotech, Lowers Price Target to $192

<a href="https://www.investegate.co.uk/announcement/gnw/nokia-oyj--0haf/inside-information-nokia-lowers-2025-operati-/8992433#:~:text=Nokia%20lowers%20its%20comparable%20operating,the%20weaker%20USD%20and%20tariffs" title="https://www.investegate.co.uk/announcement/gnw/nokia-oyj--0haf/inside-information-nokia-lowers-2025-operati-/8992433#:~:text=Nokia%20lowers%20its%20comparable%20operating,the%20weaker%20USD%20and%20tariffs">https://www.investegate.co.uk/announcement/gnw/nokia-oyj--0haf/inside-information-nokia-lowers-2025-operati-/8992433#:~:text=Nokia%20lowers%20its%20comparable%20operating,the%20weaker%20USD%20and%20tariffs</a>.

Earnings

Guidance

Nokia Expects To Report Q2 Net Sales Of €4.55 Billion And Comparable Operating Profit Of €300 Million

Scotiabank analyst Nat Schindler maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Sector Perform and raises the price target from $525 to $675.

Scotiabank Maintains Sector Perform on Meta Platforms, Raises Price Target to $675

B of A Securities analyst Dimple Gosai maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Buy and raises the price target from $185 to $201.

FSLR

B of A Securities Maintains Buy on First Solar, Raises Price Target to $201

UPDATE: President Trump Referring To Capital Gains On Houses, Not Capital Gains In General

<a href="https://www.youtube.com/watch?v=tBEuoGSrG40">https://www.youtube.com/watch?v=tBEuoGSrG40</a>
&nbsp;

Macro Economic Events

Politics

Global

Economics

General

ISHARES MSCI PHILIPPINES INVESTABLE MARKET INDEX FUND

EPHE

President Trump On Philippines, Tariffs: So Far We're Not There, We'll Probably Agree To Something

B of A Securities analyst Dimple Gosai maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Underperform and lowers the price target from $26 to $25.

MRNA

B of A Securities Maintains Underperform on Moderna, Lowers Price Target to $25

Scotiabank analyst Nat Schindler maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) with a Sector Outperform and raises the price target from $200 to $240.

GOOG

GOOGL

Scotiabank Maintains Sector Outperform on Alphabet, Raises Price Target to $240

'Nokia OYJ Lowers FY25 Operating Profit Guidance To €1.6 Billion-€2.1 Billion; Nokia Lowers 2025 Operating Profit Guidance Due To Currency; Current Tariff Landscape Is Expected To Impact Full Year Operating Profit By €50 Million To €80 Million' - Investigate.UK

BMO Capital analyst Kostas Biliouris maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Market Perform and lowers the price target from $50 to $25.

SRPT

BMO Capital Maintains Market Perform on Sarepta Therapeutics, Lowers Price Target to $25

WIIM

RTX shares are trading lower after the company lowered its financial outlook.

Press Releases

Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

Outcome of Innate Pharma's 2025 Annual General Meeting

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Comments

Innate Pharma

Noticias

Últimas noticias sobre Innate Pharma (NASDAQ:IPHA) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL